topic

P09.07 Determining potency, activation and expansion of antigen specific T cells
B Hansen, J Jørgensen, L Brix

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (Suppl 1) A28; DOI: 10.1136/jitc-2024-ITOC10.51
P11.02 A complex human tumor organoid model consisting of malignant cells, fibroblasts and immune cells enlights the effect of chemotherapy-induced senescent tumor cells on NK-cell anti-tumor responses
D Ammon, M Fabits, M Sykora, J Kabiljo, A Theophil, V Atanasova, H Dolznig, M Bergmann

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (Suppl 1) A29; DOI: 10.1136/jitc-2024-ITOC10.54
10.02 Combined anti-angiogenic treatment to increase intratumoral persistence of CAR T-cells in lung cancer brain metastases
C Eberle, J Blobner, L Dengler, JJ Herold, A Mühlbauer, T Xu, KJ Müller, N Teske, P Karschnia, S Langer, H Ishikawa-Ankerhold, M Subklewe, N Thon, J Tonn, VR Buchholz, L von Baumgarten

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (Suppl 1) A4-A5; DOI: 10.1136/jitc-2024-ITOC10.7
13.03 Empowering TCR-T cells for adoptive therapy for solid tumor through engineering with PD-1-based chimeric costimulatory switch proteins
E Noessner, C Aman, AJ Fischbeck, K Junker, J Linxweiler

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (Suppl 1) A6; DOI: 10.1136/jitc-2024-ITOC10.10
P01.06 Overcoming resistance to ICI therapy by downregulating the expression of neuropilin-1 with antisense oligonucleotides
A Maaske, N Kirchhammer, J Festag, L Rodriguez, M Buchi, S Michel, A Zippelius, F Jaschinski, R Klar

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (Suppl 1) A9-A10; DOI: 10.1136/jitc-2024-ITOC10.16
03.04 Targeted disruption of tumor-borne GDF-15-mediated immunoresistance restores immune checkpoint inhibitor activity in last-line cancer patients
M Haake, N Vashist, K Eichler, M Kist, S Genßler, I Giese, J Weigandt, K Klar, P Fettes, T Ross, J Wischhusen, E Leo, C Schuberth-Wagner

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (Suppl 1) A1-A2; DOI: 10.1136/jitc-2024-ITOC10.2
P01.07 Intracellular and extracellular biochemical activities of V-domain Ig-containing suppressor of T cell activation or VISTA
VV Sumbayev, IM Yasinska, M Abooali, S Schlichtner, E Fasler-Kan

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (Suppl 1) A10; DOI: 10.1136/jitc-2024-ITOC10.17
P01.08 Discovery of CRD1601, a potent and selective HPK1 inhibitor with robust in vivo anti-cancer activity
R Shrivastava, M Banerjee, D Pryde, S Middya, S Debnath, A Middya, D Yadav, N Mane, N Rawat, R Ghosh, A Gautam, M Padaliya, S Bano, S Basu, A Surya

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (Suppl 1) A10-A11; DOI: 10.1136/jitc-2024-ITOC10.18
P02.01 Herpesvirus entry mediator —a two-way switch for immunity
J Xia, Z Xia, K Xiao

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (Suppl 1) A12-A13; DOI: 10.1136/jitc-2024-ITOC10.21
P02.03 Ready-to-use multiplex immunofluorescence assay panels provide reliable deep spatial phenotyping for immuno-oncology applications
A Christians, J Boog, CE Jackson, MH Ingalls, A Northcutt, KE Cashion, J Rauer, A Brix, K Kwarta, JS Schwarz, T Campbell, O Braubach

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (Suppl 1) A13-A14; DOI: 10.1136/jitc-2024-ITOC10.23

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages